1011 related articles for article (PubMed ID: 18410414)
1. MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
Kempf W; Kutzner H; Cozzio A; Sander CA; Pfaltz MC; Müller B; Pfaltz M
Br J Dermatol; 2008 Jun; 158(6):1280-7. PubMed ID: 18410414
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders.
Benner MF; Jansen PM; Meijer CJ; Willemze R
Br J Dermatol; 2009 Jul; 161(1):121-7. PubMed ID: 19416236
[TBL] [Abstract][Full Text] [Related]
3. The expression of MUM1 in cutaneous T-cell lymphoproliferative disorders.
Wasco MJ; Fullen D; Su L; Ma L
Hum Pathol; 2008 Apr; 39(4):557-63. PubMed ID: 18234282
[TBL] [Abstract][Full Text] [Related]
4. Detection of clonal rearrangement of T-cell receptor genes in the diagnosis of primary cutaneous CD30 lymphoproliferative disorders.
Greisser J; Palmedo G; Sander C; Kutzner H; Kazakov DV; Roos M; Burg G; Kempf W
J Cutan Pathol; 2006 Nov; 33(11):711-5. PubMed ID: 17083688
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus in CD30 anaplastic large cell lymphoma involving the skin and lymphomatoid papulosis in South Korea.
Kim YC; Yang WI; Lee MG; Kim SN; Cho KH; Lee SJ; Lee MW; Koh JK
Int J Dermatol; 2006 Nov; 45(11):1312-6. PubMed ID: 17076712
[TBL] [Abstract][Full Text] [Related]
6. FOXP3 positive regulatory T-cells in cutaneous and systemic CD30 positive T-cell lymphoproliferations.
Gjerdrum LM; Woetmann A; Odum N; Hother C; Henrik-Nielsen R; Gniadecki R; Ralfkiaer E
Eur J Haematol; 2008 Jun; 80(6):483-9. PubMed ID: 18331599
[TBL] [Abstract][Full Text] [Related]
7. Expression of chemokines and chemokine receptors in cutaneous CD30+ lymphoproliferative disorders.
Yamaguchi T; Ohshima K; Karube K; Kawano R; Nakayama J; Suzumiya J; Kikuchi M
Br J Dermatol; 2006 May; 154(5):904-9. PubMed ID: 16634894
[TBL] [Abstract][Full Text] [Related]
8. Abnormal activator protein 1 transcription factor expression in CD30-positive cutaneous large-cell lymphomas.
Mao X; Orchard G; Russell-Jones R; Whittaker S
Br J Dermatol; 2007 Nov; 157(5):914-21. PubMed ID: 17725669
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of thymus and activation regulated chemokine and its receptor CCR4 in nodal and cutaneous anaplastic large-cell lymphomas and Hodgkin's disease.
Vermeer MH; Dukers DF; ten Berge RL; Bloemena E; Wu L; Vos W; de Vries E; Tensen CP; Meijer CJ; Willemze R
Mod Pathol; 2002 Aug; 15(8):838-44. PubMed ID: 12181269
[TBL] [Abstract][Full Text] [Related]
10. The significance of MUM1/IRF4 protein expression and IRF4 translocation of CD30(+) cutaneous T-cell lymphoproliferative disorders: a study of 53 cases.
Kiran T; Demirkesen C; Eker C; Kumusoglu H; Tuzuner N
Leuk Res; 2013 Apr; 37(4):396-400. PubMed ID: 23332472
[TBL] [Abstract][Full Text] [Related]
11. Clusterin expression in cutaneous CD30-positive lymphoproliferative disorders and their histologic simulants.
Olsen SH; Ma L; Schnitzer B; Fullen DR
J Cutan Pathol; 2009 Mar; 36(3):302-7. PubMed ID: 19220628
[TBL] [Abstract][Full Text] [Related]
12. Primary cutaneous CD30+ lymphoproliferative disorder--a 10-year follow-up. A case report and differential diagnosis.
Szpor J; Dyduch G; Gałazka K; Bahyrycz J; Stój A; Tomaszewska R
Pol J Pathol; 2009; 60(1):43-8. PubMed ID: 19670703
[TBL] [Abstract][Full Text] [Related]
13. c-Jun expression and activation are restricted to CD30+ lymphoproliferative disorders.
Drakos E; Leventaki V; Schlette EJ; Jones D; Lin P; Medeiros LJ; Rassidakis GZ
Am J Surg Pathol; 2007 Mar; 31(3):447-53. PubMed ID: 17325487
[TBL] [Abstract][Full Text] [Related]
14. Pathobiology of CD30+ cutaneous T-cell lymphomas.
Kadin ME
J Cutan Pathol; 2006 Feb; 33 Suppl 1():10-7. PubMed ID: 16412208
[TBL] [Abstract][Full Text] [Related]
15. Loss of expression of 5-hydroxymethylcytosine in CD30-positive cutaneous lymphoproliferative disorders.
De Souza A; Tinguely M; Pfaltz M; Burghart DR; Kempf W
J Cutan Pathol; 2014 Dec; 41(12):901-6. PubMed ID: 25353265
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous CD30-positive lymphoproliferative disorders with CD8 expression: a clinicopathologic study of 21 cases.
Plaza JA; Feldman AL; Magro C
J Cutan Pathol; 2013 Feb; 40(2):236-47. PubMed ID: 23189966
[TBL] [Abstract][Full Text] [Related]
17. Fascin expression in CD30-positive cutaneous lymphoproliferative disorders.
Kempf W; Levi E; Kamarashev J; Kutzner H; Pfeifer W; Petrogiannis-Haliotis T; Burg G; Kadin ME
J Cutan Pathol; 2002 May; 29(5):295-300. PubMed ID: 12100631
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis in CD30-positive lymphoproliferative disorders of the skin.
Greisser J; Doebbeling U; Roos M; Mueller B; Schmid M; Burg G; Kadin ME; Kempf W
Exp Dermatol; 2005 May; 14(5):380-5. PubMed ID: 15854132
[TBL] [Abstract][Full Text] [Related]
19. Contribution of longitudinal follow up and clinical pathological correlation in the diagnosis CD30-positive skin infiltrates.
De Souza A; Carter JB; Harris NL; Ferry JA; Duncan LM
J Cutan Pathol; 2015 Jul; 42(7):452-8. PubMed ID: 25931140
[TBL] [Abstract][Full Text] [Related]
20. CD30+ lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators.
Kempf W
J Cutan Pathol; 2006 Feb; 33 Suppl 1():58-70. PubMed ID: 16412214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
